| Literature DB >> 26548897 |
Ki-Wei Tan1,2, Christopher E M Griffiths1.
Abstract
INTRODUCTION: The immunopathogenesis of psoriasis has led to the discovery and development of several promising treatment options for psoriasis, including those that target the IL-17 and IL-23 pathways as well as small molecules that act on intracellular signaling pathways including the Janus kinase inhibitor and phosphodiesterase-4 inhibitor. Studies have demonstrated efficacy although long-term risks are not fully known. This review looks at novel systemic therapies for psoriasis that have emerged recently. AREAS COVERED: Systemic treatments for psoriasis that are in the late phase of development were reviewed, with the main focus on the efficacy and adverse effects of individual treatments. EXPERT OPINION: The future of psoriasis treatment is likely to be based on clinical, genetic and immune biomarkers that will individualize treatment and may potentially optimize disease outcome.Entities:
Keywords: IL-17; IL-23; JAK inhibitor; biologic; novel; phosphodiesterase-4 inhibitor; psoriasis; small molecules; systemic
Mesh:
Substances:
Year: 2015 PMID: 26548897 DOI: 10.1517/14656566.2016.1109636
Source DB: PubMed Journal: Expert Opin Pharmacother ISSN: 1465-6566 Impact factor: 3.889